What happened in the world of peptide research? A factual, accessibly written round-up of the newest published studies and regulator decisions. We discuss research — this is not usage or health advice. Everything Peplife supplies is Research Use Only.
★ In this edition: the FDA vote has landed and the EU has a guideline of its own
On 23 and 24 July 2026 the FDA advisory committee PCAC voted on seven peptides. Six received a positive recommendation for the US 503A bulks list, one did not. That is not an approval as a medicine and the recommendation is not binding: a formal procedure that can take years still has to follow, and it applies only in the United States.
Europe is following a very different line. Since 1 June 2026 the EMA guideline on the development and manufacture of synthetic peptides has been in force. It sets requirements for quality and impurity profile at medicine registration — not for access outside that route, and not for research material.
Scientifically, ADA 2026 was the focal point: new phase 3 figures for retatrutide, survodutide and the first oral small-molecule GLP-1 agents. Everything below is research news. Peplife peptides are Research Use Only and not intended for human or animal consumption.
1. FDA advisory committee votes: six of the seven peptides get the green light.
On 23 and 24 July 2026 the US PCAC met for two days on seven peptides. BPC-157, KPV and TB-500 each received 8 votes in favour, 6 against and 1 abstention. Semax 8-5-1, MOTS-c 7-5-2 and epitalon 7-4-1. All six are recommended for the so-called 503A bulks list, which allows US pharmacies to compound them on prescription. Emideltide (DSIP) did not make it: 6 in favour, 7 against, 1 abstention. Three qualifications matter. The recommendation is not binding, the FDA's own scientists advised against all seven because the studies were too short and had too few participants, and a formal regulatory procedure that can take years still has to follow. The decision also changes nothing about the European status. More in the pillar the FDA and peptides. Regulation: Source
2. Europe sets its own course: EMA guideline on synthetic peptides in force.
While the United States was debating compounding on prescription, the EU quietly acquired a quality framework. Guideline EMA/CHMP/CVMP/QWP/367182/2025 was adopted on 9 December 2025 and has applied since 1 June 2026. It describes what a manufacturer must demonstrate about starting materials, synthesis route, characterisation and above all the impurity profile of a synthetic peptide that ends up in a medicine. What the guideline does not do: it does not regulate access outside registration and it does not apply to research material. For RUO peptides, quality continues to be demonstrated through per-batch certificates of analysis, not through a marketing authorisation. More in the pillar EMA guideline on synthetic peptides. Regulation: Source
3. Retatrutide pushes the ceiling further at ADA 2026.
The phase 3 study TRIUMPH-1 showed roughly 20% weight loss at the highest dose after 80 weeks, rising to more than 30% after 104 weeks. In TRANSCEND-T2D-1, in participants with type 2 diabetes, HbA1c fell by about 2 percentage points. Retatrutide is a triple agonist that targets GLP-1, GIP and glucagon; that third receptor also affects energy expenditure and is probably why the figures come out higher than with dual agents. As always: these are controlled studies with supervision, dose escalation and dropouts, not results that simply repeat themselves outside that context. More in the pillar retatrutide research. Phase 3 news: Source
4. Survodutide meets the primary endpoint in fatty liver disease.
In SYNCHRONIZE-MASLD, 84% of participants on survodutide achieved a reduction in liver fat of more than 30%, compared with 24% in the placebo group. Weight loss was around 12%. Survodutide acts on two receptors at once: GLP-1 curbs appetite and improves glucose regulation, while the glucagon receptor intervenes directly in fat metabolism in the liver. That combination explains why the effect on the liver is larger than weight loss alone would predict. An important caveat: liver fat on an MRI scan is a surrogate measure. Whether it translates into less fibrosis, cirrhosis or liver failure has to emerge from longer studies with hard endpoints. More in the pillar peptides and fatty liver. Phase 3 news: Source
5. The first oral small-molecule agents are on the way.
Alongside peptides, a second generation of GLP-1 agents is arriving that is no longer a peptide but a small molecule activating the same receptor — and can therefore be taken as an ordinary tablet. In the SOLSTICE study, elecoglipron lowered HbA1c by 1.9 percentage points, compared with 1.3 percentage points for oral semaglutide. In VISTA, 10.5% weight loss was reached after 36 weeks, although about a third of participants discontinued at the highest dose. In ACCESS, aleniglipron reached 11.3% after 38 weeks and 16% after 56 weeks in the open-label phase. For the peptide field this is relevant news: it shows where the limit lies of what a peptide adds and where chemistry takes over. More in the pillar the next generation of GLP-1. Phase 3 news: Source
6. Muscle mass becomes the new yardstick for the quality of weight loss.
With potent GLP-1 agents, a substantial part of the weight lost is fat-free mass — at higher doses this rises to 40% or more. In the BELIEVE study with 507 participants, bimagrumab, an antibody that inhibits muscle breakdown, was combined with semaglutide: 22.1% weight loss, of which 92.8% came from fat mass compared with 71.8% for semaglutide alone. Bimagrumab on its own produced 100% fat loss with a 2.5% increase in fat-free mass. At ADA 2026 it was summed up like this: the share of fat-free mass in the weight lost fell from 21% to 7%. That shifts the question from how much someone loses to what exactly disappears. More in the pillar peptides and fat loss. Conference news: Source
7. GLP-1 and osteoarthritis: more pain relief than weight loss explains.
In STEP 9, knee osteoarthritis pain fell by 41.7 points on semaglutide 2.4 mg, compared with 27.5 points in the control group. The comparison with TRIUMPH-4 is more interesting: there, tirzepatide with 23% weight loss produced pain reduction comparable to semaglutide with 13%. In other words, more kilos off did not deliver proportionally more pain relief, which suggests an anti-inflammatory or otherwise mechanistic effect that is independent of weight. That is precisely the kind of observation that moves a drug class from weight management towards broader indications. More in the pillar semaglutide vs tirzepatide. Conference news: Source
8. AI-designed cancer vaccines: the bottleneck is immunogenicity, not computing power.
A mini-review in Frontiers in Genetics of 29 July 2026 sets out the state of play for peptide neoantigens selected with AI. Models such as NetMHCpan and newer transformer architectures predict which fragments of tumour protein bind to MHC molecules, and by now they do that well. The problem lies further down the chain: of the computationally selected candidates, only about 6% ultimately turn out to elicit an immune response. Predicting binding is therefore something other than predicting immunogenicity. In glioblastoma, work is under way on combinations with checkpoint inhibitors, because the vaccine alone is rarely enough. More in the pillar peptides in cancer research. Publication: Source
9. Antimicrobial peptides: explainable AI as an answer to resistance.
A review article by Islas-Ávila and colleagues in Frontiers in Drug Discovery, published on 17 July 2026, deals with antimicrobial peptides — short chains that attack bacterial membranes and therefore provoke resistance less readily than classical antibiotics. The new turn is that researchers no longer only ask which sequence works, but also why the model thinks so: explainable AI reveals which properties (charge, hydrophobicity, helix formation) carry the prediction. The bottlenecks remain the same: toxicity to the body's own cells, stability in blood and the step from in silico to the laboratory. More in the pillar AI design of peptides. Publication: Source
10. The downside of all the attention: hype, counterfeits and self-medication.
The FDA hearing also brought a less pleasant side effect. In Forbes, physician Omer Awan described on 21 July 2026 how public interest in peptides is growing far faster than the evidence, with a growing grey market as a result: products without provenance, without a certificate of analysis and with claims that rest on nothing. For anyone working with peptides the lesson is practical and dull: ask about the batch, about the certificate of analysis, about who carried out the test. Without that documentation you simply do not know what you are holding — and that is not a detail but a basic requirement. More in the pillar why we rejected a batch. Background: Source Independently tested · RUO · Sources: PubMed/PMC, NEJM, The Lancet, Nature, Frontiers, FDA, EMA, WHO, RAPS.
Previous edition: Peptide Research Bulletin — July 2026.